Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer
Journal of the Advanced Practitioner in Oncology · 27.02.2026 · 17 (2)
DOI: 10.6004/jadpro.2026.17.2.8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 27.02.2026. Verfasst von Danielle Roman und 4 weiteren Autor:innen.
Abstract (Originalsprache)
The management of metastatic hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–positive (HER2+) breast cancer continues to evolve with the development of novel targeted therapies. At JADPRO Live, presenters discussed therapies for this subtype of breast cancer, adverse events, management strategies, as well as biomarkers to consider when making treatment decisions.
Zitieren
APA
Roman, D., PharmD, BCOP, Reeder, K., & PA-C (2026). Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 17(2). https://doi.org/10.6004/jadpro.2026.17.2.8
Vancouver
Roman D, PharmD, BCOP, Reeder K, PA-C. Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology. 2026;17(2). doi:10.6004/jadpro.2026.17.2.8
BibTeX
@article{Roman2026,
author = {Roman, Danielle and PharmD and BCOP and Reeder, Kaitlyn and PA-C},
title = {Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {2},
doi = {10.6004/jadpro.2026.17.2.8}
}
EUVIMED